WallStSmart

Insmed Inc (INSM)vsSutro Biopharma (STRO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 474% more annual revenue ($606.42M vs $105.65M). STRO leads profitability with a -2.1% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

STRO

Avoid

31

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

STRO0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

STRO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$79.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-18.1%2/10

ROE of -18.1% — below average capital efficiency

Free Cash FlowQuality
$-26.62M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : STRO

Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : STRO

The primary concerns for STRO are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

STRO carries more volatility with a beta of 1.61 — expect wider price swings.

STRO is growing revenue faster at 13.8% — sustainability is the question.

STRO generates stronger free cash flow (-27M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Sutro Biopharma

HEALTHCARE · BIOTECHNOLOGY · USA

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?